Key Takeaways

  • Rayner has acquired U.S. distribution rights to Anikavisc OVD, strengthening its cataract surgery portfolio.

  • The addition of Anikavisc enhances Rayner’s ability to offer a fully bundled cataract solution alongside its Sophi phaco platform and RayOne IOL portfolio.

  • With the PMA submission for the AI-designed RayOne Galaxy complete, Rayner is positioning for a bundle-ready cataract ecosystem in 2026.

Rayner announced it has acquired the US distribution rights to Anikavisc, the ophthalmic viscosurgical device (OVD), from Visco Technologies. Financial terms of the deal were not disclosed. 

Rayner says the deal will strengthen its US cataract ecosystem and advance its mission to deliver a truly comprehensive portfolio of surgical solutions.

Anikavisc OVD is used intraoperatively during cataract surgery to protect the corneal endothelium, maintain anterior chamber depth and enable controlled surgical manipulation. Its cohesive formula is designed to provide consistent performance and enhance surgical efficiency.

The acquisition comes as Rayner is launching its FDA-approved Sophi phaco platform and continues to broaden access to the RayOne EMV Toric IOL. With the premarket approval (PMA) submission for RayOne Galaxy, the first AI-designed spiral IOL, now complete, Rayner said it is positioning itself to offer a comprehensive, bundle-ready cataract portfolio in 2026. The offering will span premium and monofocal IOLs, OVDs and advanced phaco technology.

“We’re excited about what this acquisition means for our US customers,” said Scott Corning, Vice President Americas at Rayner. “Anikavisc customers will see no changes to their current arrangements, but its reach and support will grow through our direct sales team from today. This also allows us to offer a fully bundled cataract solution, simplifying orders and streamlining purchasing, and delivers even greater value through one dedicated partner committed to innovation in cataract surgery.”